russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2122Research ArticleРЕФЕРАТABSTRACTКОРОНАРНЫЙ АНГИОГЕНЕЗ: ДИПИРИДАМОЛ ВНОВЬ НА СЦЕНЕCORONARY ANGIOGENESIS: DIPYRIDAMOLE IS BACK ON THE STAGELombardiF.LombardiF.RambaldiR.RambaldiR.20012808200104114115Copyright © Lombardi F., Rambaldi R., 20012001Lombardi F., Rambaldi R.Lombardi F., Rambaldi R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2122
European Heart Journal (2001) 22, 1151-1153.
European Heart Journal (2001) 22, 1151-1153.
ReferencesBombardini T, Picano E. The coronary angiogenetic effect of heparin: experimental basis and clinical evidence. Angiology 1997; 48: 969-76Bombardini T, Picano E. The coronary angiogenetic effect of heparin: experimental basis and clinical evidence. Angiology 1997; 48: 969-76Eckstein RW. Effects of exercise and coronary artery narrowing on coronary collateral circulation. Circ Res 1957; 5: 230-5Eckstein RW. Effects of exercise and coronary artery narrowing on coronary collateral circulation. Circ Res 1957; 5: 230-5Symons JD, Firoosmand E, Longhurst JC. Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise. A role for adenosine. Circ Res 1993; 73: 503-13Symons JD, Firoosmand E, Longhurst JC. Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise. A role for adenosine. Circ Res 1993; 73: 503-13Picano E, Michelassi C. Chronic oral dipyridamole as a ‘novel’ antianginal drug: the collateral hypothesis. Cardiovasc Res 1997; 33: 666-70Picano E, Michelassi C. Chronic oral dipyridamole as a ‘novel’ antianginal drug: the collateral hypothesis. Cardiovasc Res 1997; 33: 666-70Sacks HS, Ancona-Berk VA, Berrier J, Nagalingam R, Chalmers TC. Dipyridamole in the treatment of angina pectoris: a meta-analysis. Clin Pharmacol Ther 1998; 43: 610-15Sacks HS, Ancona-Berk VA, Berrier J, Nagalingam R, Chalmers TC. Dipyridamole in the treatment of angina pectoris: a meta-analysis. Clin Pharmacol Ther 1998; 43: 610-15Tornling G, Unge G, Skoog L, Ljungqvist A, Carlsson S, Adolfsson J. Proliferative activity of myocardial capillary wall cells in dipiridamol-treated rats. Cardiovasc Res 1978; 12: 692-5Tornling G, Unge G, Skoog L, Ljungqvist A, Carlsson S, Adolfsson J. Proliferative activity of myocardial capillary wall cells in dipiridamol-treated rats. Cardiovasc Res 1978; 12: 692-5Tornling G, Unge G, Adolfsson J, Ljungqvist A, Carlsson S. Proliferative activity of capillary wall cells in skeletal muscles in rats during long-term treatment with dipyridamole. Arzneimittelforschung 1980; 30: 622-3Tornling G, Unge G, Adolfsson J, Ljungqvist A, Carlsson S. Proliferative activity of capillary wall cells in skeletal muscles in rats during long-term treatment with dipyridamole. Arzneimittelforschung 1980; 30: 622-3Torry RJ, O’Brien DM, Connel PM, Tomanek RJ. Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am J Physiol 1992; 262: H980-H986Torry RJ, O’Brien DM, Connel PM, Tomanek RJ. Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am J Physiol 1992; 262: H980-H986Belardinelli R, Belardinelli L, Shryok JC. Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy. Eur Heart J 2001; 22: 1205-13Belardinelli R, Belardinelli L, Shryok JC. Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy. Eur Heart J 2001; 22: 1205-13Khouri EM, Gregg DE, McGranahan GM. Regression and reappearance of coronary collaterals. Am J Physiol 1971; 220: 655-61Khouri EM, Gregg DE, McGranahan GM. Regression and reappearance of coronary collaterals. Am J Physiol 1971; 220: 655-61
The authors declare that there are no conflicts of interest present.